Strategic Development of Neural Stem & Progenitor Cell Products (2019 Study) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Strategic
Development of Neural Stem and Progenitor Cell Products” report
has been added to ResearchAndMarkets.com’s offering.

While the number of adult stem cell therapies entering clinical trials
continues to expand, the development of neural stem cell therapies has
been affected by barriers to entry that include patent restrictions, the
complexity of neural stem cell applications, and burden of undertaking
costly clinical trials. Despite these limitations, dozens of companies
are now pursuing preclinical and clinical programs utilizing neural stem
and progenitor cells as therapeutic products.

Pharmaceutical companies are demonstrating an interest in neural stem
and progenitor cells. Because of their plasticity, ability to develop
into the main phenotypes of the nervous system, and unlimited capacity
for self-renewal, NSCs have been proposed for use in a variety of
pharmaceutical applications, including:

• Neurotoxicity testing
• Cellular therapies to treat CNS conditions
• Neural tissue engineering and repair
• Drug target validation and testing
• Personalized medicine

Utilization of neural stem cell products by the pharmaceutical sector
represents a thriving segment of the overall NSC marketplace. Of
interest to this community is the use of neural stem cells to heal
tissues that have a naturally limited capacity for renewal, including
the human brain and spinal cord.

Development of new drugs is extremely costly and the success rate of
bringing new compounds to the market is unpredictable. Therefore, it is
crucial that pharmaceutical companies minimize late-stage product
failures, including unexpected neurotoxic effects, that can arise when
candidate drugs enter the clinical testing stages. It is desirable to
test candidate drugs using in vitro assays of high human relevance as
early as possible. Because neural stem cells have the potential to
differentiate into nearly all the main phenotypes of the nervous system,
they represent an ideal cell type from which to design such neural
screening assays.

The concept of stem cells as a potential cure for neurodegenerative
diseases is not new. While neural stem cells (NSCs) have been explored
for more than two decades for use in treating neurodegenerative and
neurodevelopmental diseases, recent progress with developing NSCs from
human-induced pluripotent cells has accelerated interest in developing
cell-based therapeutics to target neurodegenerative diseases. As safety
and efficacy results having been obtained from preclinical and clinical
tests performed in animal models, companies have moved onto human
clinical trials using NSCs derived from different sources. For the first
time in history, there are companies developing technologies to support
the autologous generation of neural stem cells by direct cell
reprogramming.

Nearly one billion people in the aging population worldwide are affected
by neurodegenerative diseases, there are no medications currently
available to cure or stop the progression of these diseases. Available
drugs can sometimes provide symptomatic relief, but they do not address
the underlying disease, making alternative approaches badly needed. To
date, researchers have successfully isolated, propagated, and
characterized NSCs, and there are confirmed reports of neurogenesis of
transplanted NSCs in the human brain. There has also been an upsurge in
collaborative activities among pharmaceutical companies, research
institutions, and start-up companies within the neurodegenerative market.

The growth of stem cell research has exploded over the past decades, and
the market for neural stem cell and progenitor cell products is also
expanding. Claim this 211-page global strategic report to reveal the
current and future needs of the NSC marketplace, outmaneuver your
competition, and approach investors with specific and technical
knowledge of the global market for neural stem cell and progenitor cell
products.

Topics Covered

1. Report Overview

1.1 Statement of the Report

1.2 Executive Summary

2. Introduction

3. Stem Cells: A Brief Overview

3.1 Embryonic Stem Cells

3.2 Induced Pluripotent Stem Cells

3.3 Types of Specialized Cells Derived from Stem Cells

3.4 Types of Stem Cells in the Human Body

3.5 Adult Stem Cells

3.6 Characteristics of Different Types of Stem Cells

4. Neural Stem Cells: An Overview

4.1 Sources of NSCs

4.2 Basal Properties of NSCs Obtained from Different Sources

4.3 Fetal Stem Cell Transplantation for Neurodegenerative Diseases

4.4 Adult Human Neural Stem Therapeutics

5. Degenerative Diseases With Possible Cure Using NSCS

5.1 Conventional Treatments for Neurodegenerative Diseases

5.2 NSC-Based and Traditional Approaches for Neurodenerative Diseases

5.3 The Wide Gap Between Theory and Practice in NSC Applications

5.4 Types of NSCs Used for Cell Therapy Approaches

5.5 Possible Therapeutic Actions of Grafted NSCs in Neurodegenerative
Diseases

5.6 Most Recent Clinical Trials Using NSCs for Neurological Disorders

5.7 Other Clinical Trials Using NSCs for Neurodegenerative Diseases

5.8 Neurodevelopmental Disorders and Cell Therapy

6. Spinal Cord Injury And Cell Therapy

6.1 Incidence of Spinal Cord Injury

6.2 Neurological Level and Extent of Lesion in Spinal Cord Injuries

6.3 Annual and Lifetime Cost of Treating SCI Patients in the US

6.4 Medications and Other Treatments for Spinal Cord Injury

6.5 CIRM Funding for Spinal Cord Injury

6.6 Cell Therapy for Spinal Cord Injury

6.7 SCI Models and Effectiveness of Neuronal Regeneration

6.8 Clinical Trials Using Stem Cells for Spinal Cord Injury

7. Alzheimer’s Disease

7.1 Incidence of Alzheimer’s Disease

7.2 Projected Number of People Aged 65 and Older with Alzheimer’s
Disease in the US

7.3 Cost of Care by Payment Source for US Alzheimer’s Patients

7.4 Currently Available Medications for Alzheimer’s Disease

7.5 CIRM Funding for Alzheimer’s Research

7.6 Transplantation of Stem Cells for AD

8. Parkinson’s Disease

8.1 Incidence of Parkinson’s Disease

8.2 CIRM Grants Targeting Parkinson’s Disease

8.3 Current Medications for PD

8.4 Potential for Cell Therapy in Parkinson’s Disease

8.5 Gene Therapy for PD

9. Amyotrophic Lateral Sclerosis

9.1 Incidence of ALS

9.2 Symptomatic Treatments in ALS Patients

9.3 CIRM Grants Targeting ALS

9.4 Companies Focusing on Stem Cell Therapy for ALS

9.5 Cell Therapy for ALS

10. Multiple Sclerosis

10.1 Incidence of MS

10.2 Medications for MS

10.3 Neural Stem Cells’ Application in Multiple Sclerosis

10.4 Stimulation of Endogenous NSCs with Growth Factors for MS Treatment

10.5 CIRM Grants Targeting MS

11. Stroke

11.1 Incidence of Stroke

11.2 Currently Available Medication for Stroke

11.3 Stem Cell-Based Therapies for Stroke

11.4 Various Stem Cell Types Used in Stroke Experimental Studies

11.5 Ongoing Clinical Trials for Stroke Using Stem Cells

11.6 CIRM Grants Targeting Stroke

12. Market Analysis

12.1 Current Stem Cell Landscape

12.2 Major Clinical Milestones in Cell Therapy Sector

12.3 Major Anticipated Cell Therapy Clinical Data Events

12.4 Global Market for Cell Therapy Products

13. Selected Company Profiles

13.1 Asterias Biotherapeutics, Inc.

13.2 Athersys Inc

13.3 Ncardia (Formed by Merger of Axiogenesis AG / Pluriomics

13.4 Axol Bioscience

13.5 BrainStorm Cell Therapeutics

13.6 Cellular Dynamics International, Inc.

13.7 Celther Polska

13.8 Cellartis AB

13.9 CellCure Neurosciences Ltd.

13.10 Celvive, Inc.

13.11 Merck Millipore

13.12 International Stem Cell Corporation

13.13 Kadimastem Ltd.

13.14 Living Cell Technologies Limited

13.15 MEDIPOST

13.16 Neuralstem Inc.

13.17 NeuroGeneration Inc.

13.18 Neurona Therapeutics Inc.

13.19 Ocata Therapeutics Inc. (Acquired by Astellas Pharma for $379M in
Nov. 2015)

13.20 Opexa Therapeutics, Inc

13.21 ReNeuron Group PLC

13.22 RhinoCyte, Inc.

13.23 Roslin Cells Ltd.

13.24 SanBio, Inc.

13.25 Saneron CCEL Therapeutics Inc.

13.26 StemCells, Inc.

13.27 Stemedica Cell Technologies, Inc.

13.28 STEMCELL Technologies, Inc.

13.29 Talisman Therapeutics Ltd.

13.30 Xcelthera Inc.

For more information about this report visit https://www.researchandmarkets.com/research/tjg7tv/strategic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Stem
Cells